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Abstract  
Medical use of ketamine has a good safety record, but recent 
increase of misuse is worrying. We focussed on ketamine misuse 
mortality figures (UK; 1993-2006), extracted both from St George‟s 
np-SAD database and from published mortality statistics. The 23 
victims (typically males, in the 25-44 age group) self-administered 
themselves with a miscellany of psychoactive compounds and 
alcohol. Ketamine was detected in 4 cases on its own. Although 
drug identification does not necessarily imply direct contribution to 
death, the suggested ketamine high safety profile is here 
questioned. Coroners/ procurators fiscal should consider more 
routine screening for ketamine in unexpected deaths.  
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Introduction  
Ketamine is a non-competitive glutamate N-Methyl-D-Aspartate 
receptor (NMDA) antagonist. Although used as a general 
anaesthetic primarily in veterinary practice (Smith et al, 2002; Wolff 
and Winstock, 2006), it is occasionally administered to humans as 
well (BNF, 2006).  
Recreational use of ketamine started during the early 1970s in 
California and, during the 1990s, ketamine was initially sold in the 
UK as „ecstasy‟ (Schifano et al, 2006). HM Customs and Excise 
reported an emerging trend of ketamine importation into the UK 
during the last few years (ACMD, 2004). A self-selected readers‟ 
survey of a magazine aimed at clubbers found that during the 
period 1999-2003 ketamine lifetime prevalence increased from 
25.5% to 39.8%, whilst current use increased from 3.9% to 16.0% 
(McCambridge et al, 2007). When misused, ketamine can be 
injected, sniffed or smoked.  Analysis of both London and 
Manchester clubs‟ amnesty bins contents showed that ketamine 
might be the third drug of choice after cocaine and amphetamine 
(Kenyon et al, 2005). Increased risk for previous-year use of 
ketamine (OR = 8.26) was recently found among 2.5% of 590 
Canadian students who self-identified as gay, lesbian, or bisexual 
(Lampinen et al, 2006). At present, in the UK, possession of 
ketamine for personal use is not an offence; its legal status is class 
C (ACMD, 2004).     
At low doses, ketamine stimulant effects predominate. With higher 
doses, its psychotropic effects range from referential thinking, 
dissociation and depersonalization to psychotic experiences and 
include a sensation of feeling light, body distortion, absence of time 
sense, novel experiences of cosmic oneness and out-of-body 
experiences, often called the „K-hole‟ (Pomarol-Clotet et al, 2006). 
In long-term exposure, tolerance, dependence, withdrawal signs 
and flashbacks are described. Schizotypal symptoms and perceptual 
distortions may persist after cessation of ketamine use (Morgan et 
al, 2004).  
Due to its sympathomimetic activity, ketamine causes mild 
stimulation of the cardiovascular system, pupil dilation and 
bronchodilation and does not suppress respiration and gag reflex. 
Due to these characteristics, ketamine use in medical and 
veterinary settings has a good safety record (Wolff and Winstock, 
2006). Conversely, administration of the drug in high doses can 
cause cardiovascular and respiratory toxicity (Smith, 2002) and the 
increase in its unregulated use outside controlled environments may 
be a cause for concern. In fact, recreational ketamine users may 
experience numbness of the limbs, analgesia, change in the body 
temperature and vomiting. There is a risk that the user can choke 
on his vomit. Difficulty with balance, combined with numbness, 
muscle weakness and impaired perception can result in falls, 
trauma or burns (Jansen, 2000). Risks from the setting have also 
included drowning, death by hypothermia from lying outside in 
winter, traffic accidents and becoming a crime victim (e.g. „date 
rape‟; Jansen, 2000; Smith, 2002; Scott-Ham and Burton, 2005). 
Despite the reported increased use of ketamine as a recreational 
drug, relatively few reports of fatalities attributed to ketamine 
poisoning, either alone or in combination, have been documented. 
Gill and Stajic (2000) reviewed 87 ketamine-positive deaths 
occurring in New York City over a two-year period (1997 to 1999), 
but only 12 were non-hospital deaths due to acute polydrug misuse 
intoxications. In no instance was a fatal intoxication caused 
exclusively by ketamine. Between 1978 and 1997 the Institute of 
Legal Medicine in Hanover, Germany, examined 17 fatal autoerotic 
deaths, all involving males with an average age of about 37 years. 
Apart from ketamine, other compounds identified at post mortem 
included: alcohol, chloroform and a propane-butane gas mixture 
(Breitmeier et al, 2003).  
Because of the paucity of ketamine misuse mortality data, the aim 
of this report was to focus on those figures that were available for 
the UK (1993-2006).  
 
Methods 
To gather together all the available ketamine misuse mortality 
figures, two different approaches were combined: a) data were 
extracted from the National Programme on Substance Abuse Deaths 
(np-SAD) database, St George‟s, University of London for the time 
frame July 1997-December 2006; b) data based on drug-poisoning 
mortality statistics published by the General Register Offices (GROs) 
for England/Wales and Scotland were collected, together with data 
provided to the np-SAD by the GRO for N Ireland from January1993 
to December 2006.  Since its inception, the np-SAD has been 
regularly receiving coroners' information on drug-related deaths 
amongst both addicts and non-addicts in the UK. To be recorded in 
the np-SAD database, cases must meet one or more of the 
following criteria: presence of one or more psychoactive substances 
directly implicated in death; history of dependence or abuse of 
psychoactive drugs; presence of controlled drugs at necroscopic 
examination. The coroners‟ response rate has been estimated to 
have been as high as about 90-95% (Ghodse et al, 2006).  
Ketamine-related deaths were defined here as: “text search 
identified ketamine written in the coroner‟s report (other illegal 
drugs may also be written)”. Data from np-SAD were not included 
in the total number of cases derived from other records. Cases 
where ketamine was present as a result of being administered for 
medical reasons were excluded from this study.   
 Results  
We identified 23 deaths in the UK during the period 1993-2006 
where ketamine was mentioned, either on the death certificate or in 
the np-SAD coroners‟ report. Eighteen cases were notified directly 
to the np-SAD (Table 1) and a further 5 cases were identified from 
GRO sources. Aggregating the information for these two sources of 
data, we found that these deaths mostly occurred in the 1999-2006 
time-frame, with numbers increasing over time.  Most victims were 
males (19/23) and in the 25-44 age group; 21 cases were recorded 
in England and Wales. At post mortem toxicological examination, 
ketamine was detected in 4 cases on its own. For these cases, 
poisoning was the cause of death in all cases and the coroner‟s 
verdict was accidental in 3 cases and suicide in 1 case. In the 
remaining victims, alcohol (8 cases), opiates/opioids (10 cases), 
benzodiazepines (7 cases), and cocaine (6 cases) were mostly 
identified here in conjunction with ketamine. Most (13/18) of the 
subjects notified to the np-SAD were known as drug addicts.  
 
Discussion 
To the best of our knowledge, the present report constitutes the 
largest available collection of ketamine misuse mortality data from 
both the UK and elsewhere. In this report, we described 4 cases 
where ketamine was detected on its own, somewhat questioning the 
ketamine high safety profile suggested elsewhere (Degenhardt, 
2005). Most of the cases involved a miscellany of different 
compounds and alcohol suggesting that, in combination with other 
drugs, ketamine lethality risk is probably increased. One might 
wonder if the real cause of death, in polydrug cases, was due to a 
particular pharmacokinetic interaction and/or to a synergistic effect 
of the two drugs.  
A possible limitation of the present study is given by our definition 
of ketamine „related‟ deaths, which was as comprehensive as 
possible. The fact that a drug was recorded as being present post 
mortem does not necessarily imply that it contributed directly to the 
death. Furthermore, changes in coroners‟ reporting over time 
cannot be excluded here.  
Ketamine is probably not routinely screened for in toxicology tests 
(ACMD, 2004). It is here suggested that coroners and procurators 
fiscal should be encouraged to consider more routine screening for 
ketamine in unexpected deaths.  
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 Table 1: Summary results for 23 ketamine cases notified to 
either the National Programme on Substance Abuse Deaths 
(np-SAD; 18 fatalities) or the General Register Offices 
(GROs) occurring in the UK (1993-2006)  
 
 
np-SAD Variable np-SAD Results 
Year of death 1999: 2; 2000: 2; 2001: 1; 2002: 3; 2003: 1; 2004: 2; 2005: 4; 2006: 3 
Gender Male 16; Female 2 
Age (years) Average = 32.74; range: 19.8- 49.4. 
15-24 = 4; 25-34 = 9; 35-44 = 3; 45-54 = 2 
Ethnicity White = 17, Not known = 1 
Country of birth  England = 13; Scotland = 2; Germany = 1; Spain = 1; USA = 1 
Occupation Employed (manual = 3; non-manual = 9); unemployed = 5; student = 1 
Living arrangements With others = 10; alone = 6; squat = 2 
Addiction/drug abuse 
history 
Yes = 13; No = 2; Not known = 3 
Prescribed medication Yes = 6 (including methadone in 1 case and diazepam in 2 cases); No=6; 
Not known=6 
 
Region of death Greater London = 9; Merseyside = 2; Derbyshire = 1; Dorset = 1; 
Hertfordshire = 1; Nottinghamshire = 1; Surrey = 1; Brighton & Hove = 2 
Incident site Home = 8; other specified residential place = 2; industrial site = 1; place 
of recreation = 1; river = 1; Not known = 5 
Cause(s)/Mechanisms of 
death 
 Ketamine & methadone toxicity 
 Bronchopneumonia, hypoxic brain damage, cardio-respiratory 
arrest due to drug toxicity 
 Combined GHB, amphetamine & ketamine toxicity 
 Drug abuse, bronchial asthma 
 Drug overdose (morphine & ketamine) 
 Ketamine & alcohol poisoning 
 Opiate poisoning 
 MDMA & ketamine overdose 
 Drowning 
 Complications of mixed drug intoxication, due to ingestion of 
alcohol, cannabis, ketamine, diazepam, MDMA and heroin, 
followed by prolonged unconsciousness 
 Stab wound to chest  
 Pulmonary oedema, cardiac arrhythmias and drug intoxication 
 Heroin poisoning 
 Cerebral and pulmonary oedema, mixed drug poisoning 
 Cerebral and pulmonary oedema, cocaine intoxication  
 Respiratory depression, multiple drug poisoning 
 Ketamine toxicity 
 Ecstasy, ketamine and GHB toxicity 
Drugs present at post 
mortem  
 Alcohol, methadone, ketamine; 
 Ecstasy, morphine/diamorphine, opiates, ketamine, 
benzodiazepines; 
 Amphetamine, ketamine, ecstasy, cannabis, GHB; 
 Alcohol, amphetamines, ketamine; 
 Ethanol, ketamine, morphine; 
 Alcohol, ketamine, cannabis; 
 Morphine, ketamine, cocaine, codeine; 
 MDMA, ketamine;  
 Diazepam, ethanol, ketamine, temazepam, opiate-type 
substance; 
 Alcohol, cannabis, ketamine, diazepam, MDMA, heroin; 
 Ketamine only (x 2);  
 Ecstasy, ketamine, ephedrine; 
 Heroin, ketamine, temazepam; 
 Ethanol, cocaine & metabolites, ketamine, morphine; 
 Cocaine & metabolites, diazepam & metabolites, ketamine, 
cannabinoids; 
 MDMA, MDA, methylamphetamine, ketamine, amphetamine, 
cocaine & metabolites, cannabis metabolites; 
 Ecstasy, ketamine, cocaine, GHB. 
Circumstances of death Whilst drinking with others (x 2); whilst clubbing with others; injecting 
with partner; snorted whilst with others; collapsed during illegal rave; 
drowned; taken prior to killing himself with a knife; took with a range of 
other stimulants before engaging in gay sex with group of new 
acquaintances; overheated whilst wearing rubber body suit; took to excess 
trying to calm herself down; consumed range of drugs over period of 2 
days at various gay venues. Not known = 6 
Verdict Accident /misadventure = 11; open = 2; suicide = 1; dependent abuse of 
drugs = 1; abuse of drugs = 1; non-dependent abuse of drugs = 1; self-
administered overdose of drugs = 1 
  
Additional cases from 
GRO sources (1993-
2006) 
England & Wales - ONS data 
Three deaths in the period 1993-2002. All died of accidental poisoning. 2 
males and 1 female; ages within the range 20-49 years. Drugs mentioned: 
2 x ketamine alone; 1 ketamine + co-proxamol 
 
Scotland (1994 to 2006) 
A 26 year-old female, died in 1997. Cause of death recorded on the death 
certificate as: 1a - septic shock syndrome; 1b - buttock abscess; 1c - 
chronic drug abuse. Toxicology identified: ketamine, lignocaine, diazepam, 
temazepam, morphine 
 
Northern Ireland (1997-2005) 
A 35 year-old male, died in 2001. Cause of death recorded on the death 
certificate as: 1a – aspiration of vomit; 1b – poisoning by ketamine, 
temazepam and alcohol. 
 
 
